ClinicalTrials.gov
ClinicalTrials.gov Menu

Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01899326
Recruitment Status : Unknown
Verified January 2016 by Murali Janakiram, Albert Einstein College of Medicine, Inc..
Recruitment status was:  Active, not recruiting
First Posted : July 15, 2013
Last Update Posted : January 12, 2016
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Murali Janakiram, Albert Einstein College of Medicine, Inc.

July 11, 2013
July 15, 2013
January 12, 2016
December 2012
March 2015   (Final data collection date for primary outcome measure)
  • Success rate of stem cell mobilization (SCM) using filgrastim and desipramine to collect > 5 x 10^6 cluster of differentiation (CD)34/kg in patients with multiple myeloma (MM) who are first time mobilizers or unexposed to alkylating agents [ Time Frame: Day 5 ]
    Standard descriptive statistics will be used to summarize the data, including means, medians, standard deviations and ranges for continuous variables, and frequencies for categorical variables. The success rates observed in first-time mobilizers, along with corresponding 95% binomial confidence intervals, will be estimated.
  • Success rate of SCM using filgrastim and desipramine to achieve a total collection of > 5 x 10^6 CD34/kg in patients with MM who failed prior mobilization or were exposed to alkylator therapy or are predicted to be difficult to mobilize [ Time Frame: Day 5 ]
    Standard descriptive statistics will be used to summarize the data, including means, medians, standard deviations and ranges for continuous variables, and frequencies for categorical variables. The success rates observed in predicted difficult mobilizers, along with corresponding 95% binomial confidence intervals, will be estimated.
Same as current
Complete list of historical versions of study NCT01899326 on ClinicalTrials.gov Archive Site
  • Average number of days of apheresis required to collect > 5 x 10^6 CD34+/kg [ Time Frame: Up to 1 week after completion of study treatment ]
    Standard descriptive statistics will be used to summarize the data, including means, medians, standard deviations and ranges for continuous variables, and frequencies for categorical variables.
  • Incidence of adverse events graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4 [ Time Frame: Up to 1 week after completion of study treatment ]
    Standard descriptive statistics will be used to summarize the data, including means, medians, standard deviations and ranges for continuous variables, and frequencies for categorical variables.
  • Time to neutrophil engraftment: first of three consecutive days with absolute neutrophil count (ANC) > 500/ul or first day with ANC > 1000/ul in the absence of growth factor support [ Time Frame: Up to 1 week after completion of study treatment ]
    Standard descriptive statistics will be used to summarize the data, including means, medians, standard deviations and ranges for continuous variables, and frequencies for categorical variables.
  • Time to platelet engraftment: first of three days of platelets > 20,000/ul without transfusion [ Time Frame: Up to 1 week after completion of study treatment ]
    Standard descriptive statistics will be used to summarize the data, including means, medians, standard deviations and ranges for continuous variables, and frequencies for categorical variables.
  • Average number of days of apheresis required to collect > 5 x 10^6 CD34+/kg [ Time Frame: Up to 1 week after completion of study treatment ]
    Standard descriptive statistics will be used to summarize the data, including means, medians, standard deviations and ranges for continuous variables, and frequencies for categorical variables.
  • Adverse events graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4 [ Time Frame: Up to 1 week after completion of study treatment ]
    Standard descriptive statistics will be used to summarize the data, including means, medians, standard deviations and ranges for continuous variables, and frequencies for categorical variables.
  • Time to neutrophil engraftment: first of three consecutive days with absolute neutrophil count (ANC) > 500/ul or first day with ANC > 1000/ul in the absence of growth factor support [ Time Frame: Up to 1 week after completion of study treatment ]
    Standard descriptive statistics will be used to summarize the data, including means, medians, standard deviations and ranges for continuous variables, and frequencies for categorical variables.
  • Time to platelet engraftment: first of three days of platelets > 20,000/ul without transfusion [ Time Frame: Up to 1 week after completion of study treatment ]
    Standard descriptive statistics will be used to summarize the data, including means, medians, standard deviations and ranges for continuous variables, and frequencies for categorical variables.
Not Provided
Not Provided
 
Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant
Pilot Clinical Study of GCSF in Combination With Desipramine for Autologous Stem Cell Mobilization in Multiple Myeloma
This pilot clinical trial studies how well desipramine hydrochloride and filgrastim works for stem cell mobilization in patients with multiple myeloma undergoing stem cell transplant. Giving colony-stimulating factors, such as filgrastim, and other drugs, such as desipramine hydrochloride, helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored.

PRIMARY OBJECTIVES:

I. To study efficacy, safety, harvest kinetics and engraftment kinetics of patients undergoing autologous stem cell mobilization, mobilized with a combination of granulocyte colony-stimulating factor (GCSF) (filgrastim) with desipramine (desipramine hydrochloride) (G+D).

II. To analyze polymorphisms of adrenergic receptor beta 2 (ADRB2) and adrenergic receptor beta 3 (ADRB3) genes that correlate with mobilization efficiency.

OUTLINE:

Patients receive desipramine hydrochloride orally (PO) daily on days -3 to +4 and filgrastim PO twice daily (BID) on days 1-4. Stem cell collection begins on day 6.

After completion of study treatment, patients are followed up 1 week after completion of stem cell collection.

Interventional
Not Applicable
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • DS Stage I Plasma Cell Myeloma
  • DS Stage II Plasma Cell Myeloma
  • DS Stage III Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Drug: Desipramine Hydrochloride
    Given PO
    Other Names:
    • Norpramin
    • Pertofrane
  • Biological: Filgrastim
    Given PO
    Other Names:
    • G-CSF
    • Nivestim
    • r-metHuG-CSF
  • Other: Laboratory Biomarker Analysis
    Correlative studies
Experimental: Treatment (desipramine, filgrastim)
Patients receive desipramine hydrochloride PO daily on days -3 to +4 and filgrastim PO BID on days 1-4. Stem cell collection begins on day 6.
Interventions:
  • Drug: Desipramine Hydrochloride
  • Biological: Filgrastim
  • Other: Laboratory Biomarker Analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
9
40
Not Provided
March 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients eligible for autologous stem cell transplant for multiple myeloma; planned use of filgrastim (GCSF) for stem cell mobilization
  • Ability to give informed consent
  • Glomerular filtration rate (GFR) > 30 ml/minute
  • Liver function tests < 2.5 x upper limit of normal (ULN)
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 or less
  • Based on prior therapy patients will be classified into two categories:

    • Initial mobilizers with no exposure to alkylators
    • Remobilizers or with prior exposure to alkylators or with greater than 5 cycles of lenalidomide therapy prior to mobilization

Exclusion Criteria:

  • Use of a monoamine oxidase inhibitor (MAO-I) during or within 2 weeks of desipramine therapy
  • Concomitant therapy with any drugs shown to have major interactions with desipramine
  • Concurrent use of drugs that are contraindicated with desipramine
  • Myocardial infarction in preceding 4 weeks; history of uncontrolled cardiac arrhythmias or family history of sudden cardiac death; baseline corrected QT (QTc) > 460 msec
  • Active alcohol abuse
  • Bipolar disorder
  • Untreated active major depression
  • History of seizures in the past 3 years
  • Pregnancy and lactation; refusal to use adequate contraception
  • Uncontrolled thyroid disease
  • GCSF or pegfilgrastim use within 14 days prior to enrollment
  • Bortezomib, Revlimid or thalidomide use within 7 days of enrollment
  • Patients with sickle cell disease
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01899326
2012-230
NCI-2013-01212 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
11-010
2012-230 ( Other Identifier: Albert Einstein College of Medicine )
P30CA013330 ( U.S. NIH Grant/Contract )
Yes
Not Provided
Not Provided
Murali Janakiram, Albert Einstein College of Medicine, Inc.
Albert Einstein College of Medicine, Inc.
National Cancer Institute (NCI)
Principal Investigator: Murali Janakiram Albert Einstein College of Medicine, Inc.
Albert Einstein College of Medicine, Inc.
January 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP